Business / Finance

RSS

Patterson third quarter revenues grew 3% to $825.0 million

Patterson Companies, Inc. today said it is forecasting sales of approximately $825.0 million for the third quarter of fiscal 2011 ended January 29, compared to $820.1 million in the year-earlier quarter.

19 Feb 2011

Abbott increases company's quarterly dividend 9% to 48 cents per share

The board of directors of Abbott today increased the company's quarterly common dividend 9 percent to 48 cents per share.

19 Feb 2011

Angiotech executes Settlement and License Termination Agreement with Rex Medical

Angiotech Pharmaceuticals, Inc. today announced that its subsidiary, Angiotech Pharmaceuticals, Inc., has executed a Settlement and License Termination Agreement with Rex Medical, LP, providing for the full and final settlement and/or dismissal of all claims arising under the the License, Supply, Marketing and Distribution Agreement between Angiotech US and Rex, dated March 13, 2008.

19 Feb 2011

China Medical Technologies third quarter revenues increase 30.0% to RMB223.9 million ($33.9M)

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the third fiscal quarter ended December 31, 2010 ("3Q FY2010") today.

19 Feb 2011

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

Merck Canada announced today a $6.8 million investment in AmorChem, a Quebec life sciences venture capital fund. This is the latest investment made by Merck following a commitment made in 2010 to invest an incremental $100 million over five years in biopharmaceutical research and development in Quebec.

19 Feb 2011

Apria Healthcare fourth quarter revenues decrease 1.6% to $527.7 million

Apria Healthcare Group Inc., a quality, cost-efficient provider of home healthcare products and services in the United States, today announced its financial results for the quarter and year ended December 31, 2010.

18 Feb 2011

LifePoint fourth quarter revenues decrease 5.5% to $36.3 million

LifePoint Hospitals, Inc. today announced results for the fourth quarter and year ended December 31, 2010.

18 Feb 2011

Chelsea prices underwritten public offering of 8.75 million shares of common stock

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of 8.75 million shares of its common stock at a price of $4.00 per share which will result in gross proceeds of $35 million.

18 Feb 2011

HMS fourth quarter revenues increase 31.4% to $87.2 million

HMS Holdings Corp. today announced financial results for its fourth quarter and full year ended December 31, 2010.

18 Feb 2011

Healthspring fourth quarter revenues increase 29.4% to $50.9 million

HealthSpring, Inc. today announced its results for the fourth quarter and year ended December 31, 2010. HealthSpring's 2010 results include one month's contribution from the operations of Bravo Health, Inc., which was acquired by HealthSpring on November 30, 2010, and transaction expenses related to the acquisition.

18 Feb 2011

Safeguard Scientifics' 2010 partner company aggregate revenue exceeds $400 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for 2010 exceeded $400 million, beating previously issued guidance of $360 million to $385 million.

18 Feb 2011

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

18 Feb 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, securities in a registered offering to a single life sciences institutional investor. The Company may use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.

18 Feb 2011

NHI fourth quarter normalized FFO improves to $0.72 per basic and diluted common share

National Health Investors, Inc. announced today its normalized Funds From Operations ("FFO") and net income for the three months and year ended December 31, 2010.

18 Feb 2011

3M announces acquisition of Hybrivet Systems

3M announced today it has acquired Hybrivet Systems Inc., a leading provider of instant-read products to detect lead and other contaminants and toxins. Terms of the transaction were not disclosed.

17 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Spectranetics fourth quarter revenues decrease 1% to $29.3 million

Spectranetics Corporation today reported financial results for the quarter and full year ended December 31, 2010.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Urologix granted additional cure period to regain NASDAQ compliance

Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,

17 Feb 2011

Business / Finance

Patterson third quarter revenues grew 3% to $825.0 million

Abbott increases company's quarterly dividend 9% to 48 cents per share

Angiotech executes Settlement and License Termination Agreement with Rex Medical

China Medical Technologies third quarter revenues increase 30.0% to RMB223.9 million ($33.9M)

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

Apria Healthcare fourth quarter revenues decrease 1.6% to $527.7 million

LifePoint fourth quarter revenues decrease 5.5% to $36.3 million

Chelsea prices underwritten public offering of 8.75 million shares of common stock

HMS fourth quarter revenues increase 31.4% to $87.2 million

Healthspring fourth quarter revenues increase 29.4% to $50.9 million

Safeguard Scientifics' 2010 partner company aggregate revenue exceeds $400 million

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

NHI fourth quarter normalized FFO improves to $0.72 per basic and diluted common share

3M announces acquisition of Hybrivet Systems

Inspire announces strategic corporate restructuring on its eye care business

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Spectranetics fourth quarter revenues decrease 1% to $29.3 million

Inspire fourth quarter revenues increase 2% to $30.3 million

Urologix granted additional cure period to regain NASDAQ compliance

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News